title: The Hymenolepis diminuta-golden hamster (Mesocricetus auratus) model for the evaluation of gastrointestinal anticestode activity.
abstract: A novel laboratory anticestode assay was developed using Hymenolepis diminuta in the hamster. The commercial anticestode compounds, praziquantel, bunamidine, and niclosamide were active against patent infections of Hymenolepis diminuta in golden hamsters (Mesocricetus auratus) when given orally at 3.125, 100, and 200 mg/kg, respectively. The gastrointestinal nematode anthelmintics, cambendazole and mebendazole, were active at 50 mg/kg. Rafoxanide (fasciolicide) was active at 25 mg/kg, the lowest level tested. The coccidiostat, nicarbazin, was active at experimental levels (800 mg/kg and up). The anthelmintic-ectoparasiticide (endectocide), ivermectin, was inactive against the tapeworm at 0.5 mg/kg, as expected.
authors.affiliation: Merck Research Laboratories, PO Box 2000, Rahway, New Jersey 07065, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Ostlind
authors.forename: W G
authors.initials: WG
authors.lastname: Mickle
authors.forename: S K
authors.initials: SK
authors.lastname: Smith
authors.forename: S
authors.initials: S
authors.lastname: Cifelli
authors.forename: D V
authors.initials: DV
authors.lastname: Ewanciw
mesh_terms: D000284:Administration, Oral; D000578:Amidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000923:Anticestodal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002159:Cambendazole / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006224:Cricetinae; D004064:Digestive System / Q000469:parasitology*; D004195:Disease Models, Animal; D006925:Hymenolepiasis / Q000188:drug therapy*; D006926:Hymenolepis / Q000187:drug effects* / Q000302:isolation & purification; D007303:Insect Vectors / Q000469:parasitology; D007421:Intestine, Small / Q000469:parasitology; D007559:Ivermectin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008463:Mebendazole / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008647:Mesocricetus; D009528:Nicarbazin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009534:Niclosamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011223:Praziquantel / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011888:Rafoxanide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011897:Random Allocation; D014231:Tribolium / Q000469:parasitology
chemical_list: D000578:Amidines; D000923:Anticestodal Agents; D002159:Cambendazole; D009528:Nicarbazin; D011888:Rafoxanide; D011223:Praziquantel; D007559:Ivermectin; D008463:Mebendazole; D009534:Niclosamide; C100222:bunamidine